Glioma targeted therapy: insight into future of molecular approaches
Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …
gliomas occur among all ages, more often seen in adults, which males are more susceptible …
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
The discovery of immune checkpoint inhibitors (ICIs) has now been universally
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
Patients with hematological malignancies are at increased risk of severe COVID-19
outcomes due to compromised immune responses, but the insights of these studies have …
outcomes due to compromised immune responses, but the insights of these studies have …
The myeloid cell compartment—cell by cell
K Bassler, J Schulte-Schrepping… - Annual review of …, 2019 - annualreviews.org
Myeloid cells are a major cellular compartment of the immune system comprising
monocytes, dendritic cells, tissue macrophages, and granulocytes. Models of cellular …
monocytes, dendritic cells, tissue macrophages, and granulocytes. Models of cellular …
Trial watch: peptide-based vaccines in anticancer therapy
Peptide-based anticancer vaccination aims at stimulating an immune response against one
or multiple tumor-associated antigens (TAAs) following immunization with purified …
or multiple tumor-associated antigens (TAAs) following immunization with purified …
Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition
J Li, Y Ye, Z Liu, G Zhang, H Dai, J Li, B Zhou, Y Li… - Nature cancer, 2022 - nature.com
Phagocytosis is required for the optimal efficacy of many approved and promising
therapeutic antibodies for various malignancies. However, the factors that determine the …
therapeutic antibodies for various malignancies. However, the factors that determine the …
Trial watch: TLR3 agonists in cancer therapy
ABSTRACT Toll-like receptor 3 (TLR3) is a pattern recognition receptor that senses
exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in …
exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in …
GPNMB: a potent inducer of immunosuppression in cancer
The immune system is comprised of both innate and adaptive immune cells, which, in the
context of cancer, collectively function to eliminate tumor cells. However, tumors can actively …
context of cancer, collectively function to eliminate tumor cells. However, tumors can actively …
[HTML][HTML] Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
RE Sanborn, MJ Pishvaian, MK Callahan… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Phase 1/2 dose-escalation and expansion study evaluating varlilumab, a fully
human agonist anti-CD27 mAb, with nivolumab in anti-PD-1/L1 naïve, refractory solid …
human agonist anti-CD27 mAb, with nivolumab in anti-PD-1/L1 naïve, refractory solid …
Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity
N Heemskerk, M Gruijs, AR Temming… - The Journal of …, 2021 - Am Soc Clin Investig
Most clinically used anticancer mAbs are of the IgG isotype, which can eliminate tumor cells
through NK cell–mediated antibody-dependent cellular cytotoxicity and macrophage …
through NK cell–mediated antibody-dependent cellular cytotoxicity and macrophage …